Complete opinion here, but a quick thought on the COVID critical trial change. I feel like it may be more of a business financial decision. With rumors of less virulent covid strains we may just be speeding things up to see if keeping the trial is worth the $$ and effort.
I know most here just assume that 4 shots will be a slam dunk, but keep in mind 4 shots is a theory based on the 14 day results of the 62 critical after 2 shots It's an unknown and now with mtnbc BTD(s), and NP positively giddy about Nash and known data (calling it the "best" one in the proactive video over even cancer) we may decide to go after longhaulers, Nash and cancer over critical just because we have solid data for these and not amarex data coupled with slow enrollment numbers and severe trial already in hold.

Just my thoughts on the decision. I'm okay with whatever gets us to approval first and tough decisions may need to be made for the overall good. Kinda like when the FDA said no more EIND, just finish the trial so if it works we can just help more people quicker instead of doing paperwork. Unfortunate that it's the speed of science.